Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori
| Autor: | Hala M.T. El-Zimaity, Antone R. Opekun, D.Y. Graham, M. R. Carlson, G. Belson |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Combination therapy Adolescent Tetracycline Pilot Projects Pharmacology Ranitidine Gastroenterology Helicobacter Infections Anti-Infective Agents Internal medicine Metronidazole Drug Resistance Bacterial medicine Organometallic Compounds Humans Pharmacology (medical) Aged Hepatology biology Helicobacter pylori business.industry Anti-ulcer Agent Middle Aged biology.organism_classification Anti-Ulcer Agents Confidence interval Treatment Outcome Bismuth Subcitrate Patient Compliance Drug Therapy Combination Female Antacids business medicine.drug Tablets |
| Zdroj: | Alimentary pharmacologytherapeutics. 21(2) |
| ISSN: | 0269-2813 |
| Popis: | Summary Background: Current anti-Helicobacter pylori treatment regimens are costly and because of the increasing antibiotic resistance, are becoming ineffective. Aim: To evaluate a triple-layer tablet containing 100 mg bismuth subcitrate, 250 mg metronidazole, and 250 mg tetracycline in a single triple-layer tablet. Methods: H. pylori-infected adult patients received bismuth–metronidazole–tetracycline (two tablets, t.d.s.) and ranitidine (300 mg) once daily for 14 days. Efficacy was determined using 13C-urea breath testing. Results: Thirty-three of 35 enrolled patients were available for evaluation; using the protocol-specified modified intention-to-treat analysis, five failed treatment, two were lost to follow-up (cure rate per-protocol = 85.7%, intention-to-treat = 78.7%). The cure rate among metronidazole-susceptible strains was 100% (22 of 22) (95% confidence interval 84–100%) compared with 55% (five of nine intention-to-treat) (95% confidence interval 21–86%) among metronidazole-resistant strains. In four cases, therapy was truncated at 4–7 days because of side-effects; yet the treatment was effective in three. The three metronidazole-susceptible but clarithromycin-resistant infections were cured. Conclusion: This novel triple-layer tablet combination therapy was effective in all patients with metronidazole-susceptible H. pylori and many of those with resistant organisms. A greater degree of acid suppression may further improve effectiveness. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text